George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 455.50
Bid: 452.00
Ask: 455.50
Change: 0.00 (0.00%)
Spread: 3.50 (0.774%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 455.50
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Crystallisation of Business Unit & Issue of Shares

20 Nov 2019 13:30

RNS Number : 0949U
Polar Capital Holdings PLC
20 November 2019
 

Polar Capital Holdings plc

20 November 2019

Partial Crystallisation of Business Unit and issue of shares

 

Polar Capital Holdings plc ("Polar Capital" or the "Company") announces the partial crystallisation of a set of Preference Shares held by Andrew Holliman and Richard Wilson, co-heads of the Polar Capital North America Team and managers of the Polar Capital North American Fund. This partial crystallisation is expected to be immediately earnings enhancing for shareholders. Based on the results for the financial year ended 31 March 2019, the impact of the crystallisation would have been an earnings enhancement of around 1p per share1.

 

Background

As set out at the time of the Company's admission to AIM, Polar Capital has structured its fund management operations in such a way that the fund management teams are placed in separate business units. Each business unit is a separate profit centre and the fund managers responsible receive each year a payment which comprises a share of their unit's core operating profit (operating profit before performance fees and related distributions) and performance fees.

 

In addition to the remuneration structure described above, each fund management team is offered the prospect of an interest in the capital of the Company through the purchase of an individual class of preference shares in Polar Capital Partners Limited, a wholly owned subsidiary of the Company. These preference shares have been structured in such a way as to become convertible upon the occurrence of certain events, known as crystallisation events, into cash or, at the option of the Company, ordinary shares at a ratio that is intended to be earnings enhancing for the Group. At the election of the holders of the preference shares, they may crystallise all or part of their preference shares, or retain the balance, if any, for a further crystallising event at a subsequent date.

 

From the effective date of crystallisation, the fund managers concerned cease to be eligible to receive a proportion of their share of the business unit's core operating profit which has been crystallised and simultaneously going forward will receive a proportionally reduced interest in their performance fees.

 

 

North American Team business unit crystallisation

Andrew Holliman and Richard Wilson have elected to crystallise one third of their preference shares in relation to the Polar Capital North American Fund.

 

Under the terms of the preference shares the partial crystallisation value is calculated as at 31 March 2019 and either satisfied in cash, or at the option of the Company, by issue of new ordinary shares. The Company has elected to satisfy the consideration by the issue of new ordinary shares.

 

The partial crystallisation is in relation to the crystallisation period ended 31 March 2019. The initial crystallisation value is to be satisfied by the issue of up to 1,442,064 new ordinary shares, in tranches as described below. This value is re-calculated at each of the first, second, and third anniversaries of 31 March 2019, based on the profits of the business unit in the 12 months ended on the respective anniversary. If the result of the re-calculation provides for a smaller cash or share consideration, then the amounts paid or shares issued to the owners of the preference shares are adjusted accordingly. The effect of such re-calculation is to adjust downwards any consideration and there can never be an increase in the Crystallisation Value. In return for this delivery of new ordinary shares, the North American team will be forfeiting one third of the interest in their core operating profit in relation to the Polar Capital North American Fund for the financial year ended 31 March 2019.

 

Under the terms of the preference shares 10 percent of the new ordinary shares are issued immediately with the balance of 30 percent of the new ordinary shares due (subject to the re-calculation described above) on or as soon as practicable after each crystallisation anniversary.

 

As a result, the Company will issue a total of 144,206 new ordinary shares in respect of this partial crystallisation which will rank pari passu with the Company's existing ordinary shares at the time of issue.

 

The Company's current issued share capital is 96,464,735 ordinary shares and following admission of the new ordinary shares the total ordinary shares in issue will be 96,608,941.

 

Mr Holliman and Mr Wilson retain two-thirds of their class of preference shares which remain convertible upon certain future events and reflect the continued economic interest that the managers have in the North American business unit.

 

1 Presented for illustrative purposes based on the year end results for 31 March 2019 and assuming the partial crystallisation occurred as at 31 March 2019.

 

For further information please contact:

Polar Capital +44 (0)20 7227 2700

Gavin Rochussen (Chief Executive)

John Mansell (Executive Director)

Samir Ayub (Finance Director)

 

Numis Securities Limited - Nomad and Joint Broker +44 (0)20 7260 1000

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

 

Peel Hunt LLP - Joint Broker +44 (0)20 7418 8893

Guy Wiehahn

Andrew Buchanan

 

Camarco +44 (0)20 7757 4995

Ed Gascoigne-Pees

Monique Perks

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEADFEAAXNFFF
Date   Source Headline
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results
19th Oct 20222:52 pmRNSDirector/PDMR Shareholding
13th Oct 20227:00 amRNSAuM Update
29th Sep 202210:33 amRNSHolding(s) in Company
7th Sep 20224:18 pmRNSResult of AGM
31st Aug 20222:03 pmRNSForm 8.3 - Diurnal Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.